A Phase 1 interventional study of Paracetamol and Metformin Hydrochloride in Overweight or Obese, sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 330 studies in Overweight with a site in China — 123 open to participants now, 166 under way, 43 of them phase 3. Overweight · China.
Among the 330 studies in Overweight with a site in China, this one is the 267th largest by enrollment of the 296 interventional ones that give a count, is one of 66 that started in 2025, is one of 82 in phase 1, and was the 153rd registered.
3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.
Browse Overweight studies →123 of the 330 studies in Overweight with a site in China are open now. Recruiting first, the newest first:
Chendu DIAO Pharmaceutical Group CO., LTD. · Sites in China
Ages 18–65
The First Hospital of Jilin University · Sites in China
Ages 18–65
Pfizer · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Brazil and 7 more countries
Ages 18+
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–55
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
330 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 88 · Phase 2 47 · Phase 3 66 · Phase 4 12
First in 2005; this study’s year is marked. 66 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 78 across 3,132 interventional studies indexed under Overweight.
Median enrollment 120 across the 296 interventional studies, 375 across the 34 observational. Of the 145 that completed or were terminated, 9 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
183 of 330 have an industry lead sponsor. The 10 most frequent:
BrightGene Bio-Medical Technology Co., Ltd. is the lead sponsor of 18 studies on the registry; 3 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
BrightGene Bio-Medical Technology Co., Ltd. has 9 studies filed under Overweight — fewer than ten, so there is no comparison to draw.
65 of the studies in Overweight with a site in China that are under way reach primary completion within a year, 15 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06884293Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | 2026-12-31 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07230119Phase 3Beijing QL Biopharmaceutical Co.,LtdA Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1) | 2027-05-29 |
| NCT07274137Phase 3MindRank AI LtdA Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE) | 2027-06 |
Add all 65 to your calendar (.ics) → With an account.
Among the 330 studies in Overweight with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the influence of BGM0504 injection on gastric emptying and Pharmacokinetics of metformin and warfarin in overweight or obese participants
Inclusion Criteria: √ Have a (BMI) of greater than or equal to (≥)28 kilogram per square meter (kg/m²) or ≥24 kg/m2 and less than (\<) 28 kg/m².
√ Willing and agreeable to commit to the duration of the study and undergo study procedures as instructed by the clinic staff.
Exclusion Criteria: √ History of chronic or acute pancreatitis.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive Paracetamol on Day1 and Day70, Metformin on Day4 and Day73, Warfarin on Day7 and Day77. Participants receive maintenance dose 10 mg (from D42 to Day 77) with dose escalation starting from 2.5 mg(on Day 14 and Day 21), 5 mg(on Day 28 and Day 35) and then 10 mg BGM0504 administered subcutaneously (SC) once weekly (QW).
Drug: Paracetamol · Drug: Metformin Hydrochloride · Drug: Warfarin · Drug: BGM0504
oral, postprandial
Oral , Fasting
Oral , Fasting
Administered SC
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t)of Paracetamol
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t) of Paracetamol
Time frame: From Day1 to Day72
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Paracetamol
Pharmacokinetics (PK): Maximum observed plasma drug concentration (Cmax) of Paracetamol
Time frame: From Day1 to Day72
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t) of Metformin
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t)of Metformin
Time frame: From Day4 to Day76
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin
Time frame: From Day4 to Day76
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t) of Warfarin
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC0-t) of Warfarin
Time frame: From Day7 to Day84
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Warfarin
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Warfarin
Time frame: From Day7 to Day84
Area Under the Stable-State Concentration Versus Time Curve (AUC0-∞,ss ) of BGM0504
Area Under the Stable-State Concentration Versus Time Curve (AUC0-∞,ss ) of BGM0504
Time frame: From Day14 to Day69
Time to Maximum Concentration (Tmax) of Metformin and Warfarin
Time to Maximum Concentration (Tmax) of Metformin and Warfarin
Time frame: From Day1 to Day84
Terminal Half-life (t1/2) of Paracetamol
Terminal Half-life (t1/2) of Paracetamol
Time frame: From Day1 to Day72
Ran from Mar 2025 to primary completion in Jul 2025, 4 months.
Of 212 industry-sponsored phase 1 interventional studies under Overweight, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 4 months is below that.
Counting every sponsor, half of 231 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BGM0504
BrightGene Bio-Medical Technology Co., Ltd. →